X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (80255) 80255
Publication (9773) 9773
Book Review (1438) 1438
Book Chapter (576) 576
Book / eBook (292) 292
Conference Proceeding (141) 141
Dissertation (66) 66
Magazine Article (28) 28
Newspaper Article (20) 20
Reference (14) 14
Newsletter (7) 7
Trade Publication Article (7) 7
Data Set (6) 6
Presentation (5) 5
Report (4) 4
Web Resource (4) 4
Paper (3) 3
Government Document (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (55085) 55085
index medicus (44365) 44365
animals (33505) 33505
oncology (23238) 23238
female (22561) 22561
cancer (16454) 16454
mice (15471) 15471
male (14716) 14716
expression (12364) 12364
cell biology (12296) 12296
cell line, tumor (11609) 11609
biochemistry & molecular biology (10649) 10649
signal transduction (10510) 10510
growth-factor receptor (9332) 9332
research (9235) 9235
epidermal growth factor (9036) 9036
middle aged (8762) 8762
breast cancer (8692) 8692
proteins (8248) 8248
apoptosis (7995) 7995
phosphorylation (7907) 7907
receptor, epidermal growth factor - metabolism (7676) 7676
analysis (7673) 7673
cells, cultured (7527) 7527
chemotherapy (7451) 7451
tumors (7283) 7283
rats (7257) 7257
aged (7254) 7254
gene expression (7242) 7242
care and treatment (7189) 7189
pharmacology & pharmacy (7096) 7096
adult (7077) 7077
signal transduction - drug effects (7075) 7075
article (6928) 6928
receptor (6898) 6898
activation (6736) 6736
health aspects (6515) 6515
kinases (6446) 6446
mutation (6288) 6288
antineoplastic agents - therapeutic use (5912) 5912
metastasis (5881) 5881
receptor, epidermal growth factor - antagonists & inhibitors (5816) 5816
cell proliferation - drug effects (5679) 5679
research article (5549) 5549
genetic aspects (5511) 5511
antineoplastic agents - pharmacology (5457) 5457
medicine (5434) 5434
cells (5218) 5218
physiological aspects (5101) 5101
cell line (5071) 5071
receptors (4960) 4960
multidisciplinary sciences (4803) 4803
breast neoplasms - pathology (4719) 4719
receptor, epidermal growth factor - genetics (4691) 4691
egfr (4647) 4647
immunohistochemistry (4628) 4628
breast neoplasms - drug therapy (4619) 4619
therapy (4612) 4612
cell proliferation (4551) 4551
medicine & public health (4489) 4489
prognosis (4455) 4455
gene-expression (4282) 4282
in-vitro (4217) 4217
epidermal growth factor - pharmacology (4213) 4213
growth (4166) 4166
dose-response relationship, drug (4117) 4117
apoptosis - drug effects (4091) 4091
development and progression (4091) 4091
breast neoplasms - metabolism (4085) 4085
lung neoplasms - drug therapy (4056) 4056
epidermal growth factor receptors (3953) 3953
breast-cancer (3919) 3919
treatment outcome (3857) 3857
endocrinology & metabolism (3851) 3851
tumor cells, cultured (3834) 3834
proliferation (3823) 3823
medicine, research & experimental (3796) 3796
gefitinib (3767) 3767
lung cancer (3758) 3758
cancer therapies (3750) 3750
neurosciences (3690) 3690
immunology (3669) 3669
science (3659) 3659
survival (3586) 3586
inhibition (3566) 3566
cell division - drug effects (3550) 3550
ligands (3542) 3542
receptor, erbb-2 - metabolism (3493) 3493
biology (3485) 3485
inflammation (3455) 3455
in-vivo (3450) 3450
tyrosine (3429) 3429
epidermal-growth-factor (3414) 3414
physiology (3400) 3400
rodents (3340) 3340
angiogenesis (3282) 3282
epidermal growth factor receptor (3282) 3282
growth factors (3240) 3240
blotting, western (3186) 3186
carcinoma, non-small-cell lung - drug therapy (3182) 3182
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (209) 209
UTL at Downsview - May be requested (13) 13
UofT at Mississauga - Stacks (13) 13
Online Resources - Online (12) 12
Collection Dvlpm't (Acquisitions) - Closed Orders (11) 11
Collection Dvlpm't (Acquisitions) - Vendor file (9) 9
UofT at Scarborough - Stacks (4) 4
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (2) 2
Trinity College (John W Graham) - Stacks (2) 2
Dentistry (Harry R Abbott) - Stacks (1) 1
Earth Sciences (Noranda) - Stacks (1) 1
Engineering & Comp. Sci. - Stacks (1) 1
Providence Healthcare - Reference (1) 1
Providence Healthcare - Stacks (1) 1
St. Michael's Hospital - Stacks (1) 1
Toronto East General Hospital - Stacks (1) 1
Trinity College (John W Graham) - Storage (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (80284) 80284
Chinese (220) 220
French (121) 121
Japanese (100) 100
German (99) 99
Russian (46) 46
Spanish (37) 37
Hungarian (24) 24
Polish (17) 17
Korean (10) 10
Portuguese (8) 8
Danish (5) 5
Italian (5) 5
Norwegian (5) 5
Turkish (4) 4
Dutch (3) 3
Arabic (2) 2
Czech (2) 2
Croatian (1) 1
Hebrew (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer, ISSN 0008-543X, 10/2014, Volume 120, Issue 19, pp. 2980 - 2985
BACKGROUND Targeting a single pathway in pancreatic adenocarcinoma (PC) is unlikely to affect its natural history. We tested the hypothesis that simulataneous... 
pancreatic cancer | erlotinib signaling | randomized phase II | IGF‐1R | cixutumumab | EGFR | targeted treatment | Erlotinib signaling | Targeted treatment | Randomized phase II | Pancreatic cancer | Cixutumumab | IGF-1R | CARCINOMA-CELLS | DUCTAL ADENOCARCINOMA | MONOCLONAL-ANTIBODY | SINGLE-AGENT CETUXIMAB | BREAST-CANCER | INHIBITION | K-RAS | ONCOLOGY | THERAPEUTIC TARGET | C-MET | RESISTANCE | Erlotinib Hydrochloride | Pancreatic Neoplasms - metabolism | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Receptor, Epidermal Growth Factor - drug effects | Male | Insulin-Like Growth Factor I - drug effects | Pancreatic Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - metabolism | Adenocarcinoma - metabolism | Adult | Deoxycytidine - adverse effects | Female | Quinazolines - administration & dosage | Drug Administration Schedule | Deoxycytidine - administration & dosage | Pancreatic Neoplasms - pathology | Kaplan-Meier Estimate | Treatment Outcome | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Disease-Free Survival | Signal Transduction - drug effects | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Quinazolines - adverse effects | Aged | Deoxycytidine - analogs & derivatives | Insulin-Like Growth Factor I - metabolism | Index Medicus | Abridged Index Medicus
Journal Article
Hepatology, ISSN 0270-9139, 04/2014, Volume 59, Issue 4, pp. 1577 - 1590
Hepatocellular carcinoma (HCC) is the most rapidly increasing cause of cancer‐related mortality in the United States. Because of the lack of viable treatment... 
FUNCTIONAL POLYMORPHISM | HEPATIC STELLATE CELLS | MODELS | GENE-EXPRESSION | TARGETS | RISK | MECHANISMS | CYP2E1 | GASTROENTEROLOGY & HEPATOLOGY | ERLOTINIB | HEPATOCARCINOGENESIS | Erlotinib Hydrochloride | Prognosis | Rats, Wistar | Carcinoma, Hepatocellular - prevention & control | Humans | Transcriptome | Hepatic Stellate Cells - metabolism | Receptor, Epidermal Growth Factor - drug effects | Hepatocytes - pathology | Male | Receptor, Epidermal Growth Factor - metabolism | Diethylnitrosamine - adverse effects | Liver Neoplasms - pathology | Phosphorylation - drug effects | Liver Cirrhosis - genetics | Hepatic Stellate Cells - pathology | Hepatocytes - drug effects | Disease Models, Animal | Hepatic Stellate Cells - drug effects | Liver Neoplasms - prevention & control | Liver Cirrhosis - etiology | Liver Cirrhosis - prevention & control | Carbon Tetrachloride - adverse effects | Cells, Cultured | Bile Ducts - physiopathology | Rats | Mice, Inbred Strains | Disease Progression | Animals | Quinazolines - therapeutic use | Carcinoma, Hepatocellular - pathology | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Cell Proliferation - drug effects | Mice | Ligation - adverse effects | Quinazolines - pharmacology | Liver cancer | Epidermal growth factor | Rodents | Mortality | Hepatology | Gene expression | Liver cirrhosis
Journal Article
Journal Article
Journal Article
Lancet, The, ISSN 0140-6736, 2009, Volume 373, Issue 9674, pp. 1525 - 1531
Summary Background Use of cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor (EGFR), has the potential to increase survival in... 
Internal Medicine | GROWTH-FACTOR RECEPTOR | 1ST-LINE TREATMENT | MEDICINE, GENERAL & INTERNAL | CARBOPLATIN | GEFITINIB | THERAPY | CISPLATIN | COMBINATION | GEMCITABINE | ERLOTINIB | PACLITAXEL | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Receptor, Epidermal Growth Factor - drug effects | Antibodies, Monoclonal - therapeutic use | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Vinblastine - administration & dosage | Cisplatin - administration & dosage | Young Adult | Antibodies, Monoclonal, Humanized | Vinblastine - analogs & derivatives | Aged, 80 and over | Adult | Female | Cetuximab | Carcinoma, Non-Small-Cell Lung - pathology | Proportional Hazards Models | Survival Rate | Treatment Outcome | Receptor, Epidermal Growth Factor - analysis | Carcinoma, Non-Small-Cell Lung - mortality | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Survival Analysis | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Neoplasm Staging | Chemotherapy | Research | Comparative analysis | Lung cancer, Non-small cell | Drug therapy | Health aspects | Cancer | Drugs | Studies | Data analysis | Lung cancer | Acne | Monoclonal antibodies | Clinical medicine | Kinases | Quality of life | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 06/2005, Volume 97, Issue 12, pp. 880 - 887
Background. The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib (also known as Tarceva or OSI-774) has shown promising response... 
CELL LUNG-CANCER | BREAST-CANCER | AMPLIFICATION | ONCOLOGY | CYCLIN D1 | TYROSINE KINASE | PHOSPHATIDYLINOSITOL 3-KINASE | AKT | INHIBITORS | EXPRESSION | BRAIN-TUMORS | Erlotinib Hydrochloride | Immunohistochemistry | Receptor, Epidermal Growth Factor - genetics | Phosphorylation | Area Under Curve | Humans | Middle Aged | Receptor, Epidermal Growth Factor - drug effects | Drug Resistance, Neoplasm | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Glioma - metabolism | Supratentorial Neoplasms - drug therapy | PTEN Phosphohydrolase | Glioma - pathology | Tumor Suppressor Proteins - genetics | Dacarbazine - analogs & derivatives | Protein-Serine-Threonine Kinases - antagonists & inhibitors | Phosphoric Monoester Hydrolases - drug effects | Adult | Female | Quinazolines - administration & dosage | Protein-Serine-Threonine Kinases - metabolism | Proto-Oncogene Proteins - metabolism | Proto-Oncogene Proteins - antagonists & inhibitors | Dacarbazine - administration & dosage | Phosphoric Monoester Hydrolases - genetics | Drug Administration Schedule | Supratentorial Neoplasms - pathology | Supratentorial Neoplasms - metabolism | In Situ Hybridization, Fluorescence | Proto-Oncogene Proteins c-akt | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Quinazolines - therapeutic use | Aged | Tumor Suppressor Proteins - drug effects | Mutation | Glioma - drug therapy | Care and treatment | Diagnosis | Research | Gliomas | Protein kinases | Risk factors
Journal Article
Hepatology, ISSN 0270-9139, 10/2013, Volume 58, Issue 4, pp. 1225 - 1235
Journal Article